GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis
Open Access
- 1 July 2015
- journal article
- research article
- Published by Elsevier BV in Multiple Sclerosis and Related Disorders
- Vol. 4 (4), 370-376
- https://doi.org/10.1016/j.msard.2015.06.005
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosisAnnals of Neurology, 2013
- Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosisTherapeutic Advances in Neurological Disorders, 2011
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosisEuropean Journal of Neurology, 2010
- Phase III dose‐comparison study of glatiramer acetate for multiple sclerosisAnnals of Neurology, 2010
- Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trialsMultiple Sclerosis Journal, 2003
- Multiple sclerosisThe Lancet, 2002
- European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosisAnnals of Neurology, 2001
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple SclerosisNew England Journal of Medicine, 1987